The FDA granted accelerated approval to rucaparib (Rubraca, Clovis Oncology), an oral medication for the treatment of women with a certain type of ovarian cancer.
Rucaparib is indicated for women with advanced ovarian cancer who have been treated with two or more chemotherapies, and whose tumors have a specific gene mutation (deleterious BRCA), as identified by an FDA-approved companion diagnostic test.